



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Application of Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
Serial No. 09/613,038	Docket No.: 22338-602
Filed: July 10, 2000	Group Art Unit: 1636
For: BLOCKING IMMUNE RESPONSE TO A GRAFT (Amended)	

Box Patent Application
Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Listed on the accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.


This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

1. 22 The Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.

- a) ☒ Attached is our check in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the document has been considered.

Respectfully submitted,


A handwritten signature in black ink, appearing to read 'Jeffrey P. Kushan', with a long horizontal flourish extending to the right.

Jeffrey P. Kushan
Reg. No. 43,401
Attorney for Applicant

SIDLEY AUSTIN BROWN & WOOD LLP
1501 K Street, N.W.
Washington, D.C. 20005
(202) 736-8000

Dated: June 16, 2004

JK/pmo
Enclosures




INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
	Filing Date: July 10, 2000	Group Art Unit: 1636

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

176	Alawyn IPJ, Xu Y, Basker M, Wu C, Buhler L, Lambrigts D, et al. Effects of Specific Anti-B and/or Anti-Plasma Cell Immunotherapy on Antibody Production in Baboons: Depletion of CD20- and CD22-Positive B Cells Does Not Result in Significantly Reduced Production of Anti-Gal Antibody. <i>Xenotransplantation</i> 2001; 8:157-171.
177	Aranda JM, Scornik JC, Normann SJ, Lottenberg R, Schofield RS, Pauly DF, et al. Anti-CD20 Monoclonal Antibody (Rituximab) Therapy for Acute Cardiac Humoral Rejection: A Case Report. <i>Transplantation</i> 2002; 73:907-910.
178	Agarwal A, Vieira C, Book B, Fineberg N, Sidner R, Ochs H, et al. Rituximab, Anti-CD20 Inhibits a Human in Vivo Primary and Secondary Antibody Response to Bacteriophage PhiX174. <i>Blood</i> 2001; 98:608a.
179	Agarwal A, Vieira CA, Book BK, Zeni T, Sidner RA, Fineberg NA, et al. Effect of Rituximab on Natural Antibodies in Pre-Transplant Patients. <i>American Journal Transplant</i> 2002; 2 (Suppl. 3):345.
180	Garrett HE, Groshart K, Duvall-Seaman D, Combs D, Suggs R. Treatment of Humoral Rejection with Rituximab. <i>Ann. Thoracic Surgeon</i> 2002; 74:1240-1242.
181	Gloor JM, DeGoey SR, Pineda AA, Moore SB, Prieto M, Nyberg SL, et al. Overcoming a Positive Crossmatch in Living-Donor Kidney Transplantation. <i>American Journal Transplantation</i> 2003; 3:1017-1023.
182	Monteiro I, McLoughlin LM, Fisher A, de la Torre AN, Koneru B. Rituximab with Plasmapheresis and Splenectomy in ABO-Incompatible Liver Transplantation. <i>Transplantation</i> 2003; 76:1648-1649.
183	Pierson RN, Loyd JE, Goodwin A, Majors D, Dummer JS, Mohacsi P, et al. Successful Management of an ABO-Mismatched Lung Allograft Using Antigen-Specific Immunoabsorption, Complement Inhibition, and Immunomodulatory Therapy. <i>Transplantation</i> 2002; 74:79-84.
184	Sammartino C, Pham T, Panaro F, Bogetti D, Jarzembowski T, Sankary H, et al. Successful Simultaneous Pancreas Kidney Transplantation from Living-Related Donor Against Positive Cross-Match. <i>American Journal Transplantation</i> 2004; 4:140-143.
185	Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. Rituximab for Reduction of HLA Antibodies in Patients Awaiting Renal Transplantation: Pattern of B Cell Recovery. <i>FASEB J</i> 2003; 17:C113.
186	Tyden G, Kumlien G, Fehrman I. Successful ABO-Incompatible Kidney Transplantations without Splenectomy Using Antigen-Specific Immunoabsorption and Rituximab. <i>Transplantation</i> 2003; 76:730-731.
187	Vieira CA, Agarwal A, Book BK, Sidner RA, Zeni T, Gebel HM, et al. Rituxan for Reduction of Anti-HLA Antibodies in Patients Awaiting Renal Transplantation. <i>American Journal Transplantation</i> 2002; 2:356.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 2



INFORMATION DISCLOSURE STATEMENT	Docket No. 22338-602	Application No. 09/613,038
	Applicant(s): Antonio J. Grillo-Lopez et al.	Examiner: Quang Nguyen
	Filing Date: July 10, 2000	Group Art Unit: 1636

188	Becker YT, Becker BN, Knechtle SJ, Odorico JS, D'Alessandro AM, Pirsch JD, Sollinger HW. Treatment of Steroid Resistant Rejection with a Novel Anti-B-cell Preparation, Rituximab. Transplantation 2000; 69 (8 Suppl.): S362.
189	Essell JH, Broun ER, Sigmund D, Tierney C, Devoe M, Heying K, et al. Treatment of Refractory Chronic Graft-vs-Host Disease with Infliximab. Procedure American Society Clinical Oncology 2003; 22:836.
190	McGuirk J, Dix S, Belt R. Rituximab and Immune Modulation Post Unrelated Donor Transplant as Treatment for Refractory Burkitt's-Like Lymphoma. Blood 2000; 96 (Suppl 2):242b.
191	Pivkova A, Georgievski B, Cevreska L, Panovska I, Stojanovski Z, Krstevska-Balkanov S, et al. Rituximab in the Treatment of Chronic Extensive Graft Versus Host Disease: Case Report. Presented at the 8th Annual Conference of the European Haematology Association, June 12-15, Lyon, France, 2003.
192	Sawada T, Fuchinoue S, Teraoka S. Successful A1-to-0 ABO-Incompatible Kidney Transplantation After a Preconditioning Regimen Consisting of Anti-CD20 Monoclonal Antibody Infusions, Splenectomy, and Double-filtration Plasmapheresis. Transplantation 2002; 74:1207-1210
193	Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft-versus-host disease. Bone Marrow Transplant 2001;28:121-129.
194	Ratanatharathorn V, Carson E, Reynolds C, Ayash LJ, Levine J, Yanik G, et al. Anti-CD20 Chimeric Monoclonal Antibody Treatment of Refractory Immune-Mediated Thrombocytopenia in a Patient with Chronic Graft-Versus-Host Disease. Ann Intern Med 2000;133:275-279.
195	Ratanatharathorn V, Bociek RG, Pavletic SZ, Lynch JC, Ferrara JL, Uberti JP. Prior Therapy with Anti-CD20 Chimeric Antibody (Rituximab) May Decrease the Risk of Acute Graft-Versus-Host Disease (GVHD) in Patients with Non-Hodgkin's Lymphoma Receiving Allogeneic Stem Cell Transplantation. Blood 2000; 96:391a.
196	Szabolcs P, Reese M, Yancey K, Hall R, Joanne K. Combination Treatment of Bullous Skin GHVD With Anti-CD20 and Anti-CD25 Antibodies. Blood 2000; 96 (Suppl 2):350b.
197	Thomson J, Vassiliou G, Veys P, Redmill B, Edelsten C. Epstein-Barr Virus Dacryoadenitis as a Complication of Bone Marrow Transplant in a Child with Combined Immunodeficiency. Eye 2001;15:815-816.
198	Letter from Dr. Paul F. Fehlner Dated May 27, 2004

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 2 OF 2